BiVACOR is a privately held company founded in 2008. Their staff includes world-class engineers, medical specialists, and business executives who are diligently working to advance this ground-breaking technology. Together, we have established a strong collaborative network that extends both nationally and internationally. Our world headquarters are located in Houston, Texas, USA, and our international office is in Brisbane, Australia.

BiVACOR Management

Leadership team at BiVACOR

Founder and CTO

Daniel Timms

Chief Medical Officer, and Co-Founder

John Fraser

Founded

2008

Headquarters

Houston, TX, US

Industries

Manufacturing, Science and Engineering, Health Care

BiVACOR Announces Initial Public Offering of Common Shares

Houston, Texas - September 15th, 2024 - BiVACOR, a leading medical technology company, today announced the launch of its initial public offering of common shares. The company will sell 15,000,000 common shares (15% of the company's value) conducting the IPO (initial coin offering) over our trusted bookrunners.

In total, the company will issue 100,000,000 common shares at a price of $18 per share. The shares are expected to begin trading on the NYSE under the ticker symbol "BVCR" on March 15th, 2025. EARLY INVESTORS ARE CURRENTLY ABLE TO PURCHASE THE SHARES ON PRESALE WITH THE PRICE RANGING FROM $3.2 TO $5.

"This IPO marks a significant milestone in BiVACOR's growth trajectory," said Jim Dillon, Chief Executive Officer of BiVACOR. "The proceeds from this offering will enable us to accelerate the development and commercialization of our innovative medical technologies, which are designed to improve patient outcomes and transform the healthcare landscape."

BiVACOR is a pioneering medical technology company focused on developing cutting-edge solutions for the treatment of cardiovascular and respiratory diseases. The company's flagship product, the BiVACOR Artificial Heart, is a revolutionary device that has the potential to revolutionize the treatment of end-stage heart failure by providing a reliable and durable alternative to traditional heart transplants.

"We are thrilled to introduce BiVACOR to the public market and provide investors with the opportunity to be a part of our growth story," said William Abbott, Chief Financial Officer of BiVACOR. "Our proven track record of innovation, strong management team, and robust pipeline of products position us for long-term success as we work to address the unmet medical needs of patients around the world."

About BiVACOR

BiVACOR is a medical technology company dedicated to developing innovative solutions for the treatment of cardiovascular and respiratory diseases. The company's flagship product, the BiVACOR Artificial Heart, is a game-changing device that has the potential to transform the lives of patients suffering from end-stage heart failure. With a strong commitment to research and development, BiVACOR is at the forefront of the medical technology industry, driving advancements that improve patient outcomes and enhance the delivery of healthcare worldwide.

GET IN TOUCH WITH OUR BOOKRUNNER AND BECOME EARLY INVESTOR IN BIVACOR

For information regarding BiVACOR shares please signup and contact our bookrunners